AI-generated from publicly available materials.Illumina has introduced the BioInsight platform, a comprehensive software environment designed to enhance the analysis of multiomics datasets, ahead of the 2026 ASHG meeting.
The BioInsight platform aims to streamline access to Illumina’s suite of analysis tools, artificial intelligence applications, and curated data resources, allowing scientists to extract actionable insights more efficiently. This initiative stems from Illumina's recognition of a need for improved analytical capabilities to manage the complexity of multiomics data. The platform is expected to evolve, offering new features that will further empower researchers in the life sciences sector.
Among the tools available on BioInsight is SpliceA12, an advanced genomic AI model that enhances the identification of disease-relevant splice variants. This tool is particularly significant in areas such as rare disease research and hereditary cancer testing. Preliminary findings indicate that SpliceA12 outperforms previous models, detecting 17% more clinically relevant splice variants and improving splice site quantification by 34% compared to its predecessor.
The BioInsight platform also includes an updated version of Illumina’s DRAGEN software, which broadens deployment options and enhances usability across various computational environments. Furthermore, the platform operates on a flexible credits-based access system, allowing scientists to utilize the tools they need without being tied to a traditional subscription model. This adaptability is crucial for fostering innovation and facilitating the adoption of emerging technologies in multiomics research.